The first non-clogging continuous flow reactor technology

Informations projet

QFLUIDICS

N° de convention de subvention: 101162771

DOI

10.3030/101162771

Date de signature de la CE 22 Avril 2024

Date de début 1 Mars 2024

Date de fin 31 Decembre 2026

Financé au titre de

• The European Innovation Council (EIC)

Coût total

€ 3 570 490,00

Contribution de l’UE

€ 2 499 343,00

Coordonné par

QFLUIDICS
France

Periodic Reporting for period 2 - QFLUIDICS (The first non-clogging continuous flow reactor technology)

Période du rapport: 2024-11-01 au 2025-06-30

Résumé du contexte et des objectifs généraux du projet

The production of active pharmaceutical ingredients and fine chemicals in Europe needs to transform its manufacturing methods to remain competitive in a globalized world and to meet the 21st century’s climate challenges. Qfluidics, with its breakthrough liquid-tube technology, addresses this challenge by offering industries the opportunity to shift their production from batch to continuous processes, leading to reduced production costs and a smaller environmental and industrial footprint for users.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

With the support of the HE Accelerator program, we have begun the industrialization of our continuous-flow reactor while pursuing developments of relevant use cases for a key family of processes in pharmaceutical production: organometallic chemistry. In doing so, we have demonstrated our technology´s ability to perform key chemical processes that were previously impossible to achieve in continuous flow with conventional technology due to clogging issues. These processes are particularly relevant to explore in flow reactors as they are increasingly being abandoned in batch processes due to safety and quality concerns.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Our technology goes beyond the state of the art, and as confirmed by our FTO (no competitive patent in the landscape), our positioning is disruptive. Our advanced and unique continuous liquid walls flow reactors with handling solids capabilities, zero friction inside the tubes and excellent mixing properties, will revolutionize the world of chemical and pharmaceutical processing, boosting the flow chemistry and the fine chemicals and pharmaceuticals market.
By replacing traditional batch process for flow systems, they can increase efficiency, safety, yields, and higher quality chemical processing at a much smaller footprint. Our breakthrough and proprietary continuous flow reactors with superior performance and scale up opportunities to be applied at industrial level, will significantly disrupt the flow chemistry market and Qfluidics aims for a key player positioning.

The demo reactor designed by Qfluidics

Qfluidics’s business development team at Chemspec 2025 in Koln, Germany to present the MVP

Qfluidics’s business development team is at IMRET 17, conference on flow chemistry innovation

The MVP reactor, designed and produced by Qfluidics, and launched on the market in Q2 2025.